Medtronic Case Illustrates High Bar For Inequitable Conduct

By Richard Stanley (July 12, 2017, 12:39 PM EDT) -- It has been six years since the Federal Circuit issued the en banc opinion of Therasense Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Circ. 2011). In Therasense, the court raised the bar for proving inequitable conduct in patent cases. The court criticized the inequitable conduct doctrine as a plague on the entire patent system and noted that allegations of inequitable conduct were being raised in 80 percent of patent cases. The court identified numerous problems associated with the inequitable conduct doctrine, including "increased adjudication cost and complexity, reduced likelihood of settlement, burdened courts, strained U.S. Patent and Trademark Office resources, increased PTO backlog, and impaired patent quality." In response to these problems, the court tightened the standards for both the intent and materiality prongs of the inequitable conduct test....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!